Translational Research Core

转化研究核心

• 批准号: 10019346
• 负责人: Wayne M. Yokoyama
• 金额: $ 25.93万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10019346
• 关键词: African American; Animal Model; Antibodies; Archives; Asians; Award; Bioinformatics; Biological Specimen Banks; Cell model; Clinical; Clinical Data; Collection; Communities; Custom; Cytometry; Data Management Resources; Databases; Development; Enrollment; Future; Genetic; Genomics; Goals; Grant; Human Resources; Image; Immunologic Monitoring; Immunophenotyping; Infrastructure; Institutional Review Boards; Link; Metals; Outcome Measure; Patients; Process; Protocols documentation; Publications; Research; Research Personnel; Resources; Rheumatism; Rheumatoid Arthritis; Secure; Specimen; Technology; Time; Tissues; Training; Translating; Translational Research; Underrepresented Minority; Universities; Validation; Washington; Work; arthritis registry; base; biobank; bioinformatics tool; design; disease registry; expedited review; genomic data; human genomics; lupus registry; member; next generation sequencing; patient population; recruit; research and development; single cell sequencing; translational study

TRANSLATIONAL RESEARCH CORE ABSTRACT The overarching goal for the Translational Research Core is to promote, facilitate and accelerate translational science by providing the infrastructure, training and resources to support the investigators of Washington University Rheumatic Diseases Research Resource-based Center (WU-RDRRC) in their research endeavors. The highly trained TRC team will work closely with WU-RDRRC members in the design of clinical/translational studies, aid in the development of research protocols, help navigate institutional review board (IRB) requirements, assist in the collection or use of biospecimens, and facilitate access to high quality downstream analysis using genomics, bioinformatics, or immunophenotyping. In brief, the TRC team will guide investigators from concept development to genomic discovery with the ultimate goal of disseminating and/or translating the findings to practice. Towards these goals we will pursue the following Aims: 1. Develop an integrated rheumatic diseases Registry and biospecimens Repository (Biobank) that can be searched/maintained through electronic biomedical data management systems, allowing for the annotation, tracking, and sharing of tissue and databases. The Biobank maintains i) an open IRB protocol, allowing the broad collection of biospecimens linked to clinical data; ii) trained personnel to maintain IRB protocols and assist investigators in the submission of amended protocols for expedited review, recruit/enroll patients, collect/process specimens; iii) best biobanking practices for the archival of high quality biospecimens to be used in the initial or future studies by WU-RDRRC members. 2. Provide a Genomics & Bioinformatics Facility (GBF) powered by the most up-to-date Next-Generation Sequencing (NGS) technologies, including single cell sequencing, and sophisticated bioinformatics tools to enhance the secure use and analysis of human genomics data. 3. Provide an ImmunoMonitoring Facility (IMF) that offers training and access to mass cytometry as well as several panels of validated custom-designed metal-conjugated CyTOF-ready antibodies and tetramers that are currently not available commercially.

翻译研究核心摘要 转化研究核心的总体目标是促进，促进和加速翻译 科学通过提供基础设施，培训和资源来支持华盛顿的调查员 大学风湿病基于研究资源的中心（WU-RDRRC）在其研究努力中。 训练有素的TRC团队将与WU-RDRRC成员紧密合作，以设计临床/翻译的设计 研究，帮助制定研究方案，帮助导航机构审查委员会（IRB） 要求，协助收集或使用生物测量，并促进进入下游的高质量 使用基因组学，生物信息学或免疫表型分析。简而言之，TRC团队将指导 从概念开发到基因组发现的研究人员，其最终目的是传播 和/或将发现转化为练习。达到这些目标，我们将追求以下目标： 1。开发一种综合的风湿性疾病注册中心和生物种子存储库（Biobank）可以是 通过电子生物医学数据管理系统进行搜索/维护，允许 组织和数据库的注释，跟踪和共享。生物库维持i）开放式IRB 协议，允许广泛收集与临床数据相关的生物测量； ii）经过训练的人员 维护IRB协议并协助调查人员提交经修订的协议以加快 审查，招募/注册患者，收集/过程标本； iii）档案的最佳生物群实践 WU-RDRRC成员在初始或将来的研究中使用的高质量生物测量。 2。提供基因组学和生物信息学设施（GBF），该设施由最新的下一代提供支持 测序（NGS）技术，包括单细胞测序和复杂的生物信息学 增强人类基因组数据的安全使用和分析的工具。 3。提供免疫调节设施（IMF），还提供训练和访问质量细胞仪 作为几个经过验证的定制金属偶联的胞质抗体和 当前商业上尚未获得的四聚体。